Paliperidone Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidone Teva, is an atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is used to treat schizophrenia in adults and adolescents who require maintenance therapy.

GNH USA supplies Paliperidone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is an atypical antipsychotic indicated for disorders that involve dopamine dysregulation: - Schizophrenia: improves psychotic symptoms and reduces risk of relapse when administered as a monthly injection. - Schizoaffective disorder: stabilises mood and psychotic features, supporting long‑term disease control. - Maintenance therapy for schizophrenia: provides consistent plasma levels to minimise breakthrough episodes. - Adjunctive treatment in bipolar‑type conditions when other therapies are insufficient, offering a long‑acting option. - Preventive management in patients with a history of medication non‑adherence.

Paliperidone palmitate may cause a range of adverse reactions. Monitoring and patient education are essential to manage these effects.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Headache: transient and often resolves without intervention. - Weight gain: gradual increase in body mass index. - Restlessness (akathisia): feeling of inner restlessness or inability to stay still. - Drowsiness or somnolence: mild sedation, especially after the first few doses. - Constipation: reduced bowel motility leading to infrequent stools.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever, rigidity, autonomic instability. - Tardive dyskinesia: persistent involuntary movements, potentially irreversible. - Hyperglycaemia or new‑onset diabetes: significant rise in blood glucose levels. - Orthostatic hypotension: sudden drop in blood pressure upon standing, causing dizziness. - Seizures: rare occurrence, particularly in patients with a seizure history. - Elevated prolactin: galactorrhoea, menstrual disturbances, or sexual dysfunction.

Before initiating Paliperidone Teva, clinicians should assess individual risk factors and monitor patients regularly. - Cardiovascular assessment: evaluate for history of arrhythmias or QT prolongation. - Metabolic monitoring: check baseline glucose, lipid profile and weight. - Psychiatric evaluation: ensure the patient is stable and understands the injection schedule. - Pregnancy and lactation: weigh benefits against potential fetal or neonatal risks. - Drug‑interaction review: verify concomitant medications do not increase cardiac or metabolic risk. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone exposure. - QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmia. - CNS depressants (e.g., benzodiazepines, opioids): heightened sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol, atomoxetine): potential alteration in plasma levels. - Antihypertensives: may enhance orthostatic hypotension. - Antidiabetic drugs: monitor glucose as paliperidone can affect glycaemic control.